Terpenoids from Zingiber officinale (Ginger) Induce Apoptosis in Endometrial Cancer Cells through the Activation of p53

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Liu, Yang ^a,b   Whelan, Rebecca J ^c   Pattnaik, Bikash R ^b   Ludwig, Kai ^b   Subudhi, Enkateswar ^d   Rowland, Helen ^b   Claussen, Nick ^b   Zucker, Noah ^b   Uppal, Shitanshu ^b   Kushner, David M ^b   Felder, Mildred ^b   Patankar, Manish S ^b   Kapur, Arvinder ^b  

^a SHANDONG UNIVERSITY   (China)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c OBERLIN COLLEGE   (United States)

^d SIKSHA O ANUSANDHAN DEEMED TO BE UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

(6) GINGEROL; BETA CITRAL; CASPASE 3; CISPLATIN; CITRAL; GINGER EXTRACT; GINGEROL; PIFITHRIN ALPHA; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; SHOGAOL; TERPENOID DERIVATIVE; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CANCER CELL; CONTROLLED STUDY; DISTILLATION; ENDOMETRIUM CANCER; IC 50; ISOMER; MASS FRAGMENTOGRAPHY; MITOCHONDRIAL MEMBRANE POTENTIAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RADIATION; RHIZOME;

APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; ENDOMETRIAL NEOPLASMS; FEMALE; GINGER; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; PLANT EXTRACTS; TERPENES; TUMOR SUPPRESSOR PROTEIN P53;

ZINGIBER OFFICINALE;

EID: 84871724929     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053178     Document Type: Article

References (48)

1. Siegel R, Naishadham D, Jemal A, (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
2. Creasman WT, Odicino F, Maisonneuve P, Quinn MA, Beller U, et al. (2006) Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 95Suppl 1: S105-143.
3. Cohen CJ, Bruckner HW, Deppe G, Blessing JA, Homesley H, et al. (1984) Multidrug treatment of advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Obstet Gynecol 63: 719-726.
4. Gallion HH, Brunetto VL, Cibull M, Lentz SS, Reid G, et al. (2003) Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 21: 3808-3813.
5. Fleming GF, Filiaci VL, Bentley RC, Herzog T, Sorosky J, et al. (2004) Phase III randomized trial of doxorubicin+cisplatin versus doxorubicin +24-h paclitaxel+filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. Ann Oncol 15: 1173-1178.
6. Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, et al. (2004) Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 22: 2159-2166.
7. Randall ME, Filiaci VL, Muss H, Spirtos NM, Mannel RS, et al. (2006) Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 24: 36-44.
8. Thigpen JT, Brady MF, Homesley HD, Malfetano J, DuBeshter B, et al. (2004) Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol 22: 3902-3908.
9. Homesley HD, Filiaci V, Gibbons SK, Long HJ, Cella D, et al. (2009) A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study. Gynecol Oncol 112: 543-552.
10. Gehrig PA, Bae-Jump VL, (2010) Promising novel therapies for the treatment of endometrial cancer. Gynecol Oncol 116: 187-194.
11. Park EJ, Pezzuto JM, (2002) Botanicals in cancer chemoprevention. Cancer Metastasis Rev 21: 231-255.
12. Brown AC, Shah C, Liu J, Pham JT, Zhang JG, et al. (2009) Ginger's (Zingiber officinale Roscoe) inhibition of rat colonic adenocarcinoma cells proliferation and angiogenesis in vitro. Phytother Res 23: 640-645.
13. Ishiguro K, Ando T, Maeda O, Ohmiya N, Niwa Y, et al. (2007) Ginger ingredients reduce viability of gastric cancer cells via distinct mechanisms. Biochem Biophys Res Commun 362: 218-223.
14. Jeong CH, Bode AM, Pugliese A, Cho YY, Kim HG, et al. (2009) [6]-Gingerol suppresses colon cancer growth by targeting leukotriene A4 hydrolase. Cancer Res 69: 5584-5591.
15. Shukla Y, Singh M, (2007) Cancer preventive properties of ginger: a brief review. Food Chem Toxicol 45: 683-690.
16. Rhode J, Fogoros S, Zick S, Wahl H, Griffith KA, et al. (2007) Ginger inhibits cell growth and modulates angiogenic factors in ovarian cancer cells. BMC Complement Altern Med 7: 44.
17. Shukla Y, Prasad S, Tripathi C, Singh M, George J, et al. (2007) In vitro and in vivo modulation of testosterone mediated alterations in apoptosis related proteins by [6]-gingerol. Mol Nutr Food Res 51: 1492-1502.
18. Katiyar SK, Agarwal R, Mukhtar H, (1996) Inhibition of tumor promotion in SENCAR mouse skin by ethanol extract of Zingiber officinale rhizome. Cancer Res 56: 1023-1030.
19. Krell J, Stebbing J, (2012) Ginger: the root of cancer therapy? Lancet Oncol 13: 235-236.
20. Pan MH, Hsieh MC, Kuo JM, Lai CS, Wu H, et al. (2008) 6-Shogaol induces apoptosis in human colorectal carcinoma cells via ROS production, caspase activation, and GADD 153 expression. Mol Nutr Food Res 52: 527-537.
21. Nigam N, George J, Srivastava S, Roy P, Bhui K, et al. (2010) Induction of apoptosis by [6]-gingerol associated with the modulation of p53 and involvement of mitochondrial signaling pathway in B[a]P-induced mouse skin tumorigenesis. Cancer Chemother Pharmacol 65: 687-696.
22. Weng CJ, Wu CF, Huang HW, Ho CT, Yen GC, (2010) Anti-invasion effects of 6-shogaol and 6-gingerol, two active components in ginger, on human hepatocarcinoma cells. Mol Nutr Food Res 54: 1618-1627.
23. Ju SA, Park SM, Lee YS, Bae JH, Yu R, et al. (2012) Administration of 6-gingerol greatly enhances the number of tumor-infiltrating lymphocytes in murine tumors. Int J Cancer 130: 2618-2628.
24. Chen CY, Chen CH, Kung CH, Kuo SH, Kuo SY, (2008) [6]-gingerol induces Ca2+ mobilization in Madin-Darby canine kidney cells. J Nat Prod 71: 137-140.
25. Lee HS, Seo EY, Kang NE, Kim WK, (2008) [6]-Gingerol inhibits metastasis of MDA-MB-231 human breast cancer cells. J Nutr Biochem 19: 313-319.
26. Lee SH, Cekanova M, Baek SJ, (2008) Multiple mechanisms are involved in 6-gingerol-induced cell growth arrest and apoptosis in human colorectal cancer cells. Mol Carcinog 47: 197-208.
27. Wohlmuth H, Smith MK, Brooks LO, Myers SP, Leach DN, (2006) Essential oil composition of diploid and tetraploid clones of ginger (Zingiber officinale Roscoe) grown in Australia. J Agric Food Chem 54: 1414-1419.
28. Riyazi A, Hensel A, Bauer K, Geissler N, Schaaf S, et al. (2007) The effect of the volatile oil from ginger rhizomes (Zingiber officinale), its fractions and isolated compounds on the 5-HT3 receptor complex and the serotoninergic system of the rat ileum. Planta Med 73: 355-362.
29. Mo B, Vendrov AE, Palomino WA, DuPont BR, Apparao KB, et al. (2006) ECC-1 cells: a well-differentiated steroid-responsive endometrial cell line with characteristics of luminal epithelium. Biol Reprod 75: 387-394.
30. Satyaswaroop PG, Tabibzadeh SS, (1991) Extracellular matrix and the patterns of differentiation of human endometrial carcinomas in vitro and in vivo. Cancer Res 51: 5661-5666.
31. Nishida M, Kasahara K, Kaneko M, Iwasaki H, Hayashi K, (1985) [Establishment of a new human endometrial adenocarcinoma cell line, Ishikawa cells, containing estrogen and progesterone receptors]. Nihon Sanka Fujinka Gakkai Zasshi 37: 1103-1111.
32. Spinner DM, (2001) MTT growth assays in ovarian cancer. Methods Mol Med 39: 175-177.
33. Denizot F, Lang R, (1986) Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 89: 271-277.
34. Adams RP (2007) Identification of essential oil components by gas chromatography/mass spectrometry. Carol Stream, IL: Allured Pub Corp.
35. Shahzad MM, Mangala LS, Han HD, Lu C, Bottsford-Miller J, et al. (2011) Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia 13: 309-319.
36. Lee C, Park GH, Kim CY, Jang JH, (2011) [6]-Gingerol attenuates beta-amyloid-induced oxidative cell death via fortifying cellular antioxidant defense system. Food Chem Toxicol 49: 1261-1269.
37. Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, et al. (1999) A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 285: 1733-1737.
38. Yaginuma Y, Westphal H, (1992) Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res 52: 4196-4199.
39. Huang HC, Chiu SH, Chang TM, (2011) Inhibitory effect of [6]-gingerol on melanogenesis in B16F10 melanoma cells and a possible mechanism of action. Biosci Biotechnol Biochem 75: 1067-1072.
40. Zhang S, Liu Q, Liu Y, Qiao H, Liu Y, (2012) Zerumbone, a Southeast Asian Ginger Sesquiterpene, Induced Apoptosis of Pancreatic Carcinoma Cells through p53 Signaling Pathway. Evid Based Complement Alternat Med 2012: 936030.
41. Yodkeeree S, Sung B, Limtrakul P, Aggarwal BB, (2009) Zerumbone enhances TRAIL-induced apoptosis through the induction of death receptors in human colon cancer cells: Evidence for an essential role of reactive oxygen species. Cancer Res 69: 6581-6589.
42. Choudhury D, Das A, Bhattacharya A, Chakrabarti G, (2010) Aqueous extract of ginger shows antiproliferative activity through disruption of microtubule network of cancer cells. Food Chem Toxicol 48: 2872-2880.
43. Sullivan KD, Gallant-Behm CL, Henry RE, Fraikin JL, Espinosa JM, (2012) The p53 circuit board. Biochim Biophys Acta 1825: 229-244.
44. Jones SN, Roe AE, Donehower LA, Bradley A, (1995) Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378: 206-208.
45. Montes de Oca Luna R, Wagner DS, Lozano G, (1995) Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378: 203-206.
46. Honda R, Tanaka H, Yasuda H, (1997) Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 420: 25-27.
47. Hemann MT, Lowe SW, (2006) The p53-Bcl-2 connection. Cell Death Differ 13: 1256-1259.
48. Bagci EZ, Vodovotz Y, Billiar TR, Ermentrout GB, Bahar I, (2006) Bistability in apoptosis: roles of bax, bcl-2, and mitochondrial permeability transition pores. Biophys J 90: 1546-1559.